Nomograms for Prediction of Disease Recurrence in Patients with Primary Ta, T1 Transitional Cell Carcinoma of the Bladder

Hong, Sung Joon; Han, Mooyoung; Rhew, Hyun Yul; Kim, Choung‐Soo; Ryu, Soo Bang; Sul, Chong Koo; Chung, Moon Kee; Park, Tong Choon; Kim, Hyung Jin

doi:10.3346/jkms.2008.23.3.428

Cited by 32 publications

(28 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although there have been numerous attempts to establish prognostic markers for NMIBC (3,(6)(7)(8), the limited value of current markers means that new predictive indicators of BC outcome are urgently required. Due to the molecular and cellular Three-gene signature predicts disease progression of non-muscle invasive bladder cancer heterogeneity of most cancers, and the subsequent variability in biological behavior, a single pathway or gene marker, may have inherent limitations in terms of predicting cancer outcome.…”

Section: Introductionmentioning

confidence: 99%

Three-gene signature predicts disease progression of non-muscle invasive bladder cancer

Jeong

Cho

et al. 2011

Oncology Letters

View full text Add to dashboard Cite

Abstract.The clinical grades and staging methods currently employed for bladder cancer (BC) are inadequate for assessing treatment outcomes for non-muscle invasive bladder cancer (NMIBC). We have developed a clinically applicable quantitative real-time PCR (qPCR) gene signature to predict the progression of NMIBC. Three genes not previously described for BC were selected from our published progression-related gene classifier data set. Data were drawn from a previous study population and from new cases. Primary NMIBC tissue specimens (n=193) were analyzed by qPCR. Risk scores were then used to rank specimens into high-and low-risk signature groups based on their gene expression. The Kaplan-Meier method and a multivariate Cox regression model were used to identify the prognostic value of the three-gene signature for both recurrence and progression. The Kaplan-Meier estimates revealed significant differences in time-to-recurrence and progression between low-and high-risk signatures (log-rank test, p=0.011 and p<0.001, respectively). The multivariate Cox regression analysis showed that the three-gene risk signature is an independent predictor of bladder tumor progression (hazard ratio, 4.268; 95% CI, 1.542-11.814; p=0.005). In conclusion, our three-gene signature was found to be closely associated with progression among patients with NMIBC. IntroductionBladder cancer (BC), the incidence and mortality of which increases directly with age, is a heterogeneous disease that affects approxi mately 68,000 people in the United States annually (1). In Korea, BC is the second most common urological malignancy and is about five times more common in male as compared to female individuals (2). Patients diagnosed with non-muscle invasive bladder cancers (NMIBC) may have indolent, albeit recurrent, disease. However, NMIBC patients are required to receive frequent cystourethroscopy, which is inconvenient for patients. Additionally, they may experience progression to muscle invasive bladder cancer (MIBC), which potentially has a narrow window-of-cure and requires aggressive treatment (3). Therefore, predicting the course of the disease is of great value to both patients and urologists, in order for adequate management of NMIBC to occur. For example, early radical cystectomy has a superior 5-year survival rate compared to bladder-sparing surgery (4). The development of accurate and reliable biological markers would be useful for assessing aggressiveness and for predicting the prognosis of NMIBC.Previously, we undertook a microarray analysis of specimens derived from 103 primary NMIBC patients and identified an eight-gene progression-related gene classifier (5). Although there have been numerous attempts to establish prognostic markers for NMIBC (3,(6)(7)(8)

show abstract

Section: Introductionmentioning

confidence: 99%

Three-gene signature predicts disease progression of non-muscle invasive bladder cancer

Jeong

Cho

et al. 2011

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…La información que aportan estos modelos es compleja y se requieren herramientas clínicas que faciliten su uso como por ejemplo a través de los nomogramas [19,20]. Otro mecanismo para simplificar su uso es el sistema de puntuaciones utilizado en nuestro estudio y basado en los coeficientes obtenidos en cada una de las variables analizadas.…”

Section: Discussionunclassified

“…Nuestro objetivo es establecer el pronóstico y tratamiento una vez se realiza la RTU y se dispone del estudio anatomo-patológico que siempre es previo a la cistoscopia de los tres meses tras RTU. Otros modelos pronósticos al igual que nuestro estudio no incluyeron esta variable en su análisis [20,27,28]. Otra limitación viene determinada por la variable fragilidad del modelo de fragilidad conjunta.…”

Section: Discussionunclassified

Cálculo del riesgo biológico de multirrecidiva y progresión del carcinoma urotelial no músculo-invasivo mediante nuevos modelos matemáticos

Marco

Santamaría

Pontones

et al. 2014

Actas Urológicas Españolas

View full text Add to dashboard Cite

show abstract

“…La prédominance des patients de sexe masculin constatée dans notre série a déjà été rapportée par d'auteurs [5,12].…”

Section: Discussionunclassified

Les tumeurs de vessie: aspects épidémiologiques et thérapeutiques à Brazzaville

Odzébé¹,

Bouya²,

Mbon

et al. 2010

J Afr Cancer

View full text Add to dashboard Cite

Reçu le 7 janvier 2010 ; accepté le 1 er mars 2010 © Springer-Verlag France 2010Résumé Objectifs : Étudier les variables épidémiologiques et présenter les aspects thérapeutiques et évolutifs des tumeurs de vessie. Malades et méthodes : Il s'agit d'une étude rétrospective qui a porté sur des patients hospitalisés dans le service d'urologie du CHU de Brazzaville, de 1990 à 2006, pour tumeur de vessie. Pendant cette période, 82 patients ont été hospitalisés pour cette pathologie. Quarante dossiers complets ont été retenus pour l'étude. Les aspects épidémiologiques (fréquence, âge, sexe, situation géographique, facteurs de risques), diagnostiques, thérapeutiques et évolutifs ont été analysés. Résultats : Les tumeurs de vessie occupent le deuxième rang des tumeurs urogénitales après les tumeurs prostatiques, avec une fréquence de 4,78 %. L'âge moyen était de 51 ans (23-77 ans). La majorité des patients provenaient de la partie sud de notre pays. L'hématurie était le principal motif de consultation. Le diagnostic était évoqué à l'écho-graphie et à l'urographie intraveineuse. L'examen anatomopathologique réalisé chez 11 patients avait retrouvé : carcinome transitionnel, cinq cas ; carcinome épidermoïde, deux cas ; un cas respectif d'hémangiome capillaire et caverneux, de papillome, d'hyperplasie pseudoépithéliomateuse et de métaplasie glandulaire. Parmi les 40 patients, 17 (43 %) ont été traités chirurgicalement. La récidive tumorale a concerné quatre cas (23 %). Onze (27,5 %) patients sont décédés pendant la période d'étude. Conclusion : Les tumeurs de vessie observées dans le service d'urologie du CHU de Brazzaville semblent plus fréquentes dans les zones d'endémie bilharzienne. Pour citer cette revue : J. Afr. Cancer 3 (2011). Mots clés Tumeurs de vessie · Bilharziose · Traitement · CongoAbstract Objectives: To define the epidemiological variables and to appreciate the therapeutic and evolutionary aspects of bladder tumors. Patients and methods: The study is a retrospective survey of the files of patients hospitalized for bladder tumor in the Department of Urology and Andrology of Brazzaville University Hospital between 1990 and 2006. During this period, 82 patients had been hospitalized for bladder tumor. Only 40 complete files have been used for the survey. The epidemiological, diagnostic, therapeutic and evolutionary aspects have been analyzed. Results: Bladder tumors are the second most prevalent urogenital tumors after the prostate tumors, with a frequency of 4.78%. The mean age of the patients was 51 (range 23-77) years. The majority of the patients came from the southern part of the country, which is a zone of endemic bilharzia. Hematuria was the main clinical sign. The diagnosis was based on ultrasound and intravenous urography. Anatomopathological examinations performed in 11 patients revealed a predominance of transitional carcinomas of epidermoids. Among the 40 patients, 17 (43%) had been treated surgically, with 4 (23%) recidivisms. Eleven (27.5%) patients died during the period of survey. Conclusion: Bla...

show abstract

Nomograms for Prediction of Disease Recurrence in Patients with Primary Ta, T1 Transitional Cell Carcinoma of the Bladder

Cited by 32 publications

References 24 publications

Three-gene signature predicts disease progression of non-muscle invasive bladder cancer

Three-gene signature predicts disease progression of non-muscle invasive bladder cancer

Cálculo del riesgo biológico de multirrecidiva y progresión del carcinoma urotelial no músculo-invasivo mediante nuevos modelos matemáticos

Les tumeurs de vessie: aspects épidémiologiques et thérapeutiques à Brazzaville

Contact Info

Product

Resources

About